INTRODUCTION
Cancer and cardiovascular diseases are the leading causes of death in the western world. Cancer and certain cardiovascular diseases, such as atherosclerosis, are often associated with inflammation, and it has been demonstrated that chronic inflammation may be the common factor in many diseases. The clinically used anti-inflammatory drugs (steroids) are effective, but their long-term use may require increasing doses and cause unwanted side-effects, such as hypertension, oedema, ulcer, weight gain and insulin resistance. There are other types of drugs that are non-steroidal anti-inflammatory agents (NSAIDs) and have lower toxicity. The treatment of cardiovascular diseases includes a series of indications, such as cardiotonic and antiarrhythmic agents, lowering the level of low-density lipoprotein cholesterol, decreasing the blood pressure, preventing blood clots, relieving fluid buildup and managing stress hormones. Great efforts are ongoing worldwide in the search for new compounds that can selectively influence these diseases.
Plants have a long history of use in the treatment of the above diseases. Over 60% of the currently used anticancer agents are derived from natural sources. The agents include vinblastine, vincristine, the camptothecin derivatives, etoposide and paclitaxel. Trabectedin (Yondelis®), isolated from the sea squirt, Ecteinascidia turbinata, provided the first marine anticancer drug to be approved in Europe. Ingenol-3-angelate (Picato®), a metabolite found in Euphorbia peplus, has approved for the treatment of actinic keratosis. Several plant-derived agents are currently undergoing clinical development, among them flavopiridol, combretastatins and roscovitine.
The best-known example of a natural anti-inflammatory agent is salicylic acid, isolated from Salix species. Cannabidiol, a secondary metabolite in Cannabis sativa has also been approved for the treatment of inflammation in many countries in 2005. In contrast to NSAIDs that inhibit the enzyme cyclo-oxygenase, the mode of action underlying the anti-inflammatory effects of natural products, such as sesquiterpene lactones (SLs) which has been explained by mechanisms involving the inhibition of nuclear factor-kB (NF-ĸB) and the production of inflammatory cytokines. This has raised interest in SLs as prospective therapeutics for the treatment of inflammation.
A number of bioactive compounds generally obtained from terrestrial plants such as isoflavones, resveratrol, quercetin, catechin, sulforaphane, tocotrienols and carotenoids have been proven to promote cardioprotection and to reduce the risk of cardiovascular diseases. The cardioprotective effects of the various phytochemicals may be due to their antioxidative, antihypercholesterolaemic, antiangiogenic, anti-ischaemic, platelet aggregation-inhibitory and anti-inflammatory activities that reduce the risk of cardiovascular disorders. Natural products possess a broad diversity of structures and functions, and have traditionally provided substantial inspiration for drug development programs. Modern isolation and screening technologies have enhanced the search for new lead molecules and increased interest in folkmedicinal plant extracts. Secondary metabolites of the Asteraceae and Polygonaceae species can be regarded as promising starting materials for pharmaceutical discoveries, in consequence of their pharmacological potential, and in particular their noteworthy antitumour and antiinflammatory effects, which provides a rationale for screening for new active constituents from these families for the treatment of cancer and cardiovascular disorders.
AIMS OF THE STUDY
A few years ago, the research group of the Department of Pharmacognosy at the University of Szeged started a screening programme to investigate the antiproliferative activity of the species of the Asteraceae family and to identify the bioactive compounds in the selected plants. The aim of the present work as part of this project was the chemical investigation and detailed pharmacological analysis of two species belonging to the Asteraceae family. In the course of the work, pharmacological screening was extended to plants of the Polygonaceae family.
In order to achieve the aims, the main tasks were:
 A review of the literature on the Asteraceae and Polygonaceae families, from aspect of the chemistry and pharmacological properties of the plants. 
MATERIALS AND METHODS

For
RESULTS AND DISCUSSION
SCREENING OF POLYGONACEAE SPECIES FOR ANTIPROLIFERATIVE AND GIRK CHANNEL INHIBITORY ACTIVITIES
In our screening, the antiproliferative effects of 27 species belonging in the Fallopia (3), Oxyria (1), ethnomedicinal use has not been described previously.
In the course of GIRK channel inhibitory activity investigation, 51 extracts [n-hexane (A), CHCl3
(B) and aqueous MeOH (C)] of 11 species were tested at 0.01 and 0.1 mg/mL concentrations on human embryonic kidney. Among them mainly the CHCl3 (B) extracts proved to be the most active ones; P. aviculare (75 ± 5%), P. amphibia (70 ± 12%), P. persicaria (76 ± 8%), R. stenophyllus (72 ± 3%), R. patientia (74 ± 2%) and R. crispus (72 ± 2°%) showed higher than 70% inhibitory activity at 0.1 mg/mL on GIRK channels (unpublished data). The best of our knowledge, this was the first application of the GIRK channel-inhibitory assay for the screening of plant extracts. In the initial step of the phytochemical work, the dried plant materials were percolated with MeOH at room temperature; solvent-solvent extraction was then applied, which resulted in the CHCl3 or CH2Cl2 phases. All of them were subjected to a multistep chromatographic procedure in order to isolate the compounds.
INVESTIGATION
Isolation of compounds from Neurolaena lobata
The 
Isolation of compounds from Onopordum acanthium
The CHCl3 phase of O. acanthium was separated by VLC to furnish 6 main fractions (BI-VI) ( Figure   2 ). These fractions were evaluated for their inhibitory effects on COX-2 and NF-κB1 gene expression, iNOS, 5-LOX, and COX-1 and COX-2 enzymes in in vitro assays. Fractions BI, BIV and BV at 10 or 50 µg/mL exhibited significant or moderate activity in the inhibition of COX-2 gene expression(45.5 ± 8.3%, 31.5 ± 11.1% and 12.6 ± 5.7%), NO production (62.5 ± 16.5%, 102.0 ± 0.3% and 79.9 ± 6.2%) and COX-2 enzyme (63.8 ± 9.8%, 19.9 ± 8.4% and 44.9 ± 8.8%). 
Isolation of compounds from Polygonum persicaria
In the case of P. persicaria, the CHCl3 phase was fractionated by RP-VLC on silica gel (Figure 3) . The fractions were combined into 6 main fractions (B/1-B/6), and were tested for GIRK channelinhibitory activity. Fractions B/4 and B/5 displayed considerable activity, which were further separated by RP-HPLC, to yield 4 compounds (PP-1-4, 21-24) and a mixture containing the minor constituents. where previously published data were incomplete.
Compounds from Neurolaena lobata
Thirteen SLs esterified with isovaleric acid at C-8 or C-9 (in case of LOB-6) were isolated from N.
lobata. Eight of them, the germacranolide type LOB-2 (neurolenin A, 1), LOB-3 (neurolenin B, 2), LOB-5 (neurolenin D, 3), LOB-6 (neurolenin C, 4) and LOB-10 (lobatin A, 6) and the furanoheliangolide-type LOB-11 (lobatin B, 7), LOB-9 (8β-isovaleryloxy-9α-acetoxy-calyculatolide,
5)
and LOB-13 (8β-isovaleryloxy-9α-hydroxy-calyculatolide, 8), had already been isolated from this species. LOB-15 (9) and LOB-14 (10) are unusual isomeric seco-germacranolide sesquiterpenes with a bicyclic acetal moiety. LOB-18 (11) , is an 1-keto-furanoheliangolide derivative similarly to LOB-13 (8) , from which it differs only at the substitution of C-5. Lobatin B (LOB-11, 7) showed the most potent anti-inflammatory effect, comparable to those of the known inhibitors BAY and parthenolide. This was followed by 8β-isovaleryloxy-9α-acetoxycalyculatolide (LOB-9, 5), neurolenin B (LOB-3, 2) and lobatin A (LOB-10, 6). Moreover, the structure−activity analysis revealed the importance of the double bond at C-4−C-5 and C-2−C-3 and the acetyl group at C-9 for the anti-inflammatory activity.
The in vivo anti-inflammatory activity of the CH2Cl2 extract was evaluated by using a carrageenan-induced paw oedema model in rats. Both applied doses of N. lobata extract (20 and 60 mg/kg) inhibited the development of acute inflammation in rats. The suppression of local oedema formation by the higher dose was more that 50%. In vivo confirmation of the pharmacological effect raises further interest in the therapeutic potential of lobatin B (LOB-11, 7)
and related compounds.
Onopordum acanthium
The anti-inflammatory activities of the isolated compounds ( Our results reveal that secondary metabolites of Asteraceae and Polygonaceae species can be regarded as promising starting materials in the search for new pharmaceutical discoveries, in consequence of their pharmacological potential, and in particular their noteworthy antiinflammatory and antitumour effects. and understanding attitude during these years. I will forever be grateful to my family, whose love and support has enabled me to complete this work.
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